Drug Trial Radar · NCT05635305
Zoliflodacin Bioequivalence and Drug-Drug Interaction Study
Last checked: Nov 20, 2026Latest source record: Mar 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
50
Actual
Start
Nov 9, 2022
Primary completion
Feb 7, 2023
Study completion Feb 7, 2023
Sponsor
- Lead sponsor
- Global Antibiotics Research and Development PartnershipAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Parexel; KCAS
- First posted
- Dec 2, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
this study will be a Phase 1, single-dose, two parallel cohorts, open-label, randomized study in healthy subjects with Cohort 1 as bioequivalence (BE) and food effect study and Cohort 2 as a drug-drug interaction (DDI) study.
Conditions
- Healthy Volunteers
Interventions
Zoliflodacin PatheonDrug
Zoliflodacin Patheon formulation to be compared with Zoliflodacin Dr Reddy's formulation during BE study (cohort 1). Itraconazole will be administered with Zoliflodacin Patheon formulation during DDI study (cohort 2)
Primary outcomes
What the sponsor says the trial is designed to measure.
- CmaxTime frame: through study completion, an average of 5 months
- AUC(0-t)Time frame: through study completion, an average of 5 months
- AUC(0-∞)Time frame: through study completion, an average of 5 months
- clinically significant changes from baseline for vital signs: HRTime frame: through study completion, an average of 5 months
- clinically significant changes from baseline for vital signs: SBPTime frame: through study completion, an average of 5 months
- clinically significant changes from baseline for vital signs: DBPTime frame: through study completion, an average of 5 months
- clinically significant changes from baseline for ECG: PRTime frame: through study completion, an average of 5 months
- clinically significant changes from baseline for ECG: QRSTime frame: through study completion, an average of 5 months
- clinically significant changes from baseline for ECG: QTcFTime frame: through study completion, an average of 5 months
- TEAETime frame: through study completion, an average of 5 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Parexel Early Phase Clinical Unit
Berlin, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.